Tyrosine kinase inhibitors in the treatment of systemic sclerosis: From animal models to clinical trials

Current Rheumatology Reports

Volumn 13, Issue 1, 2011, Pages 21-27

  Iwamoto, Naoki ^a   Distler, Jörg H W ^b   Distler, Oliver ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Fibrosis; Imatinib; Platelet derived growth factor; Systemic sclerosis; Transforming growth factor ; Tyrosine kinase inhibitors

Indexed keywords

ABELSON KINASE; DASATINIB; GADOLINIUM; IMATINIB; NILOTINIB; OROSOMUCOID; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KINASE C DELTA; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA;

ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; DIARRHEA; DIASTOLIC DYSFUNCTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; EROSIVE GASTRITIS; FACE EDEMA; FIBROSING ALVEOLITIS; FLUID RETENTION; GENERALIZED EDEMA; HUMAN; HYPOTHYROIDISM; INFECTION; INTERSTITIAL LUNG DISEASE; KIDNEY FIBROSIS; LEG EDEMA; LIVER FIBROSIS; LUNG FIBROSIS; MOLECULARLY TARGETED THERAPY; MUSCLE CRAMP; MYALGIA; MYELOFIBROSIS; MYOFIBROBLAST; MYOPATHY; NAUSEA; NEPHROGENIC SYSTEMIC FIBROSIS; NEUTROPENIA; NONHUMAN; PERIORBITAL EDEMA; PERIPHERAL EDEMA; SIDE EFFECT; SKIN FIBROBLAST; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; UPPER RESPIRATORY TRACT INFECTION; WEAKNESS;

ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; MICE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; SCLERODERMA, SYSTEMIC;

EID: 79551525686     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-010-0142-x     Document Type: Article

References (50)

1. J Varga D Abraham 2007 Systemic sclerosis: a prototypic multisystem fibrotic disorder J Clin Invest 117 557 567 1:CAS:528:DC%2BD2sXis12htrw%3D 10.1172/JCI31139 17332883 (Pubitemid 46348510)
2. SS Baroni M Santillo F Bevilacqua, et al. 2006 Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis N Engl J Med 354 2667 2676 1:CAS:528:DC%2BD28XmtFSgtLg%3D 10.1056/NEJMoa052955 16790699
3. N Loizos L Lariccia J Weiner, et al. 2009 Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and systemic sclerosis patient sera Arthritis Rheum 60 1145 1151 1:CAS:528:DC%2BD1MXltFemsrY%3D 10.1002/art.24365 19333919
4. JF Classen D Henrohn F Rorsman, et al. 2009 Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis Arthritis Rheum 60 1137 1144 1:CAS:528:DC%2BD1MXltFemsrk%3D 10.1002/art.24381 19333949
5. D Dragun JH Distler G Riemekasten O Distler 2009 Stimulatory autoantibodies to platelet-derived growth factor receptors in systemic sclerosis: what functional autoimmunity could learn from receptor biology Arthritis Rheum 60 907 911 10.1002/art.24364 19333918
6. A Ludwicka T Ohba M Trojanowska, et al. 1995 Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma J Rheumatol 22 1876 1883 1:CAS:528:DyaK2MXpsVWjsbY%3D 8991985
7. A Yamakage K Kikuchi EA Smith, et al. 1992 Selective upregulation of platelet-derived growth factor alpha receptors by transforming growth factor beta in scleroderma fibroblasts J Exp Med 175 1227 34 1:CAS:528: DyaK38XhvVylt7g%3D 10.1084/jem.175.5.1227 1314885
8. SM Wahl 1994 Transforming growth factor b: the good, the bad, and the ugly J Exp Med 180 1587 1590 1:CAS:528:DyaK2cXmt1aitrc%3D 10.1084/jem.180.5.1587 7964446 (Pubitemid 24328550)
9. Y Asano H Ihn K Yamane, et al. 2004 Impaired Smad7-Smurf-mediated negative regulation of TGF-b signaling in scleroderma fibroblasts J Clin Invest 113 253 264 1:CAS:528:DC%2BD2cXmsVyqsg%3D%3D 14722617
10. Y Asano H Ihn K Yamane, et al. 2006 Increased expression of integrin avb5 induces the myofibroblastic differentiation of dermal fibroblasts Am J Pathol 168 499 510 1:CAS:528:DC%2BD28Xhs1agurY%3D 10.2353/ajpath.2006.041306 16436664 (Pubitemid 43271148)
11. S Sonnylal CP Denton B Zheng, et al. 2007 Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma Arthritis Rheum 56 334 344 1:CAS:528:DC%2BD2sXhsFaisLw%3D 10.1002/art.22328 17195237 (Pubitemid 46106207)
12. S Bhattacharyya W Ishida M Wu, et al. 2009 A non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylate Oncogene 28 1285 1297 1:CAS:528:DC%2BD1MXntFCqtQ%3D%3D 10.1038/onc.2008.479 19151753
13. CE Daniels MC Wilkes M Edens, et al. 2004 Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis J Clin Invest 114 1308 1316 1:CAS:528:DC%2BD2cXpsFCgtrg%3D 15520863
14. F Ciardiello G Tortora 2008 EGFR antagonists in cancer treatment N Engl J Med 358 1160 1174 1:CAS:528:DC%2BD1cXjt1ahsL4%3D 10.1056/NEJMra0707704 18337605 (Pubitemid 351398490)
15. JH Distler O Distler 2008 Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis Rheumatology (Oxford) 47 Suppl 5 v10 v11 1:CAS:528:DC%2BD1MXpvFynu7s%3D 10.1093/rheumatology/ken276
16. PM Hassoun L Mouthon JA Barbera S Eddahibi SC Flores F Grimminger, et al. 2009 Inflammation, growth factors, and pulmonary vascular remodeling J Am Coll Cardiol 54 1 Suppl S10 19 1:CAS:528:DC%2BC3cXkvVOks7o%3D 10.1016/j.jacc.2009.04. 006 19555853
17. MW Deininger SG O'Brien JM Ford, et al. 2003 Practical management of patients with chronic myeloid leukemia receiving imatinib J Clin Oncol 21 1637 1647 1:CAS:528:DC%2BD2cXptlCksb4%3D 10.1200/JCO.2003.11.143 12668652 (Pubitemid 46594119)
18. A Quintas-Cardama H Kantarjian J Cortes 2009 Imatinib and beyond-exploring the full potential of targeted therapy for CML Nat Rev Clin Oncol 6 535 543 1:CAS:528:DC%2BD1MXhtVKjsrjP 10.1038/nrclinonc.2009.112 19652654
19. HA Bradeen CA Edie T O'Hare, et al. 2006 Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyI-N nitrosourea (ENU)-based mutagenesis screen: High efficacy of drug combinations Blood 108 2332 2338 1:CAS:528:DC%2BD28XhtVCgur%2FJ 10.1182/blood-2006-02-004580 16772610 (Pubitemid 44497517)
20. JH Distler A Jungel LC Huber, et al. 2007 Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis Arthritis Rheum 56 311 322 1:CAS:528:DC%2BD2sXhsFaisL4%3D 10.1002/art.22314 17195235 (Pubitemid 46106205)
21. B Maurer J Stanczyk A Jungel, et al. 2010 MicroRNA-29, a key regulator of collagen expression in systemic sclerosis Arthritis Rheum 62 1733 1743 1:CAS:528:DC%2BC3cXhtFGmsr7F 10.1002/art.27443 20201077
22. J Pannu Y Asano S Nakerakanti E Smith, et al. 2008 Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate Arthritis Rheum 58 2528 2537 1:CAS:528:DC%2BD1cXhtVCjur7P 10.1002/art.23698 18668566
23. Y Asano 2010 Future treatments in systemic sclerosis J Dermatol 37 54 70 1:CAS:528:DC%2BC3cXjtVWgs74%3D 10.1111/j.1346-8138.2009.00758.x 20175840
24. C Beyer G Schett O Distler JH Distler 2010 Animal models of systemic sclerosis: prospects and limitations Arthritis Rheum 62 2831 2844 1:CAS:528:DC%2BC3cXhsVSqtrrO 10.1002/art.27647 20617524
25. A Akhmetshina C Dees M Pileckyte, et al. 2008 Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis FASEB J 22 2214 2222 1:CAS:528:DC%2BD1cXotlanurg%3D 10.1096/fj.07-105627 18326784 (Pubitemid 351948641)
26. A Abdollahi M Li G Ping, et al. 2005 Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis J Exp Med 201 925 935 1:CAS:528:DC%2BD2MXislOhu7w%3D 10.1084/jem.20041393 15781583 (Pubitemid 40524462)
27. S Wang MC Wilkes EB Leof, et al. 2005 Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo FASEB J 19 1 11 10.1096/fj.04-2370com 15629889 (Pubitemid 40069914)
28. H Yoshiji R Noguchi S Kuriyama, et al. 2005 Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats Am J Physiol Gastrointest Liver Physiol 288 G907 913 1:CAS:528:DC%2BD2MXktlSnsL8%3D 10.1152/ajpgi.00420.2004 15618280 (Pubitemid 40563130)
29. A Akhmetshina P Venalis C Dees, et al. 2009 Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis Arthritis Rheum 60 219 224 1:CAS:528:DC%2BD1MXhvFCjsr4%3D 10.1002/art.24186 19116940 This study demonstrated the efficacy of imatinib in Tsk-1 mice representing later, less inflammatory stages of SSc and showed the efficacy of imatinib in an animal model of established fibrosis
30. NI Chaudhary A Schnapp JE Park 2006 Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model Am J Respir Crit Care Med 173 769 776 1:CAS:528:DC%2BD28Xms1Cgsbc%3D 10.1164/rccm.200505-717OC 16415276
31. C Beham-Schmid U Apfelbeck H Sill, et al. 2002 Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis Blood 99 381 383 1:CAS:528: DC%2BD38XivF2nug%3D%3D 10.1182/blood.V99.1.381 11756197 (Pubitemid 34533009)
32. CE Bueso-Ramos J Cortes M Talpaz, et al. 2004 Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia Cancer 10 332 336 10.1002/cncr.20380 (Pubitemid 38890837)
33. L Magro M Mohty B Catteau, et al. 2009 Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease Blood 114 719 722 1:CAS:528:DC%2BD1MXpt1Wmt7g%3D 10.1182/blood-2009-02-204750 19289852 Published in the same issue as the article by Olivieri et al. [34•], this article shows encouraging results for cGvHD in an open-label study with imatinib
34. A Olivieri F Locatelli M Zecca, et al. 2009 Imatinib for refractory chronic graft-versus-host disease with fibrotic features Blood 114 709 718 1:CAS:528:DC%2BD1MXpt1Wmt7s%3D 10.1182/blood-2009-02-204156 19403889 This article also shows encouraging results for cGvHD in an open-label study with imatinib
35. H Nakasone Y Kanda H Takasaki Kanto Study Group for Cell Therapy, et al. 2010 Prophylactic impact of imatinib administration after allogeneic stem cell transplantation on the incidence and severity of chronic graft versus host disease in patients with Philadelphia chromosome-positive leukemia Leukemia 24 1236 1239 1:STN:280:DC%2BC3cvotlGqsg%3D%3D 10.1038/leu.2010.83 20428195
36. M Stadler R Ahlborn H Kamal, et al. 2009 Limited efficacy of imatinib in severe pulmonary chronic graft-versus-host disease Blood 114 3718 3719 1:CAS:528:DC%2BD1MXhtlyjsrjN 10.1182/blood-2009-07-231159 19850751
37. I Sabnani MJ Zucker ED Rosenstein, et al. 2009 A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide Rheumatology (Oxford) 48 49 52 1:CAS:528:DC%2BD1cXhsVOgsLzL 10.1093/ rheumatology/ken369
38. PP Sfikakis VG Gorgoulis CG Katsiari, et al. 2008 Imatinib for the treatment of refractory, diffuse systemic sclerosis Rheumatology (Oxford) 47 735 737 1:CAS:528:DC%2BD1cXkvFymtbc%3D 10.1093/rheumatology/ken104 (Pubitemid 351619226)
39. PL van Daele WA Dik HB Thio, et al. 2008 Is imatinib mesylate a promising drug in systemic sclerosis? Arthritis Rheum 58 2549 2552 10.1002/art.23648 18668570
40. L Chung DF Fiorentino MJ Benbarak, et al. 2009 Molecular framework for response to imatinib mesylate in systemic sclerosis Arthritis Rheum 60 584 591 1:CAS:528:DC%2BD1MXjt1Cnsrk%3D 10.1002/art.24221 19180499
41. J Kay WA High 2008 Imatinib mesylate treatment of nephrogenic systemic fibrosis Arthritis Rheum 58 2543 2548 1:CAS:528:DC%2BD1cXhtVCjur7J 10.1002/art.23696 18668587
42. JH Distler B Manger BM Spriewald, et al. 2008 Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease Arthritis Rheum 58 2538 2542 1:CAS:528: DC%2BD1cXhtVCjur7I 10.1002/art.23694 18668536
43. Spiera RF, Gordon JK, Mersten J, et al.: Imatinib Mesylate (Gleevec™) in the Treatment of Diffuse Cutaneous Systemic Sclerosis: Results of a One Year, Phase IIa, Single Arm, Open Label Clinical Trial. [abstract 2192]. Presented at the 74th Annual Scientific Meeting of American College of Rheumatology. Atlanta, GA; November 7-11, 2010.
44. R Saggar D Khanna MD Mayes, et al. 2010 Open Labeled Study Of Imatinib Mesylate (Gleevec) In The Treatment Of Systemic Sclerosis- Associated Active Interstitial Lung Disease (SSc-ILD): Preliminary Results Am J Respir Crit Care Med 181 A3991
45. J Pope D McBain L Petrlich, et al. 2010 A randomized double blind proof of concept trial of imatinib (Gleevec) in active diffuse scleroderma (dSSc) Ann Rheum Dis 69 Suppl3 410
46. Distler O, Distler JH, Varga J, et al.: A Multi-Center, Open-Label, Proof of Concept Study of Imatinib Mesylate Demonstrates No Benefit for the Treatment of Fibrosis in Patients with Early, Diffuse Systemic Sclerosis. [abstract 560]. Presented at the 74th Annual Scientific Meeting of the American College of Rheumatology. Atlanta, GA; November 7-11, 2010.
47. CE Daniels JA Lasky AH Limper, et al. 2010 Imatinib-IPF Study Investigators: Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results Am J Respir Crit Care Med 181 604 610 1:CAS:528:DC%2BC3cXhtFahsLfL 10.1164/rccm.200906-0964OC 20007927 This trial was the first randomized, placebo-controlled trial to assess the efficacy of imatinib in the treatment of fibrosis
48. N Widmer LA Decosterd C Csajka, et al. 2006 Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein Br J Clin Pharmacol 62 97 112 1:CAS:528:DC%2BD28XoslKnsL4%3D 10.1111/j.1365-2125.2006.02719.x 16842382
49. M Azuma Y Nishioka Y Aono, et al. 2007 Role of alpha1-acid glycoprotein in therapeutic antifibrotic effects of imatinib with macrolides in mice Am J Respir Crit Care Med 176 1243 1250 1:CAS:528:DC%2BD1cXpvVKmtw%3D%3D 10.1164/rccm.200702-178OC 17717205 (Pubitemid 350256478)
50. B Maurer N Busch A Jungel, et al. 2009 Tyrosine Kinase Inhibitors (TKI) Are Promising Therapeutic Agents for the Proliferative Vasculopathy in SSc [abstract] Arthritis Rheum 60 Suppl 10 1263